Stem Cell Therapy for Rotator Cuff and Tendon Injuries

Rotator cuff tears and chronic tendinopathy are among the most common reasons people search for stem cell treatment options, and the research here is more mature than in many other orthopedic applications. This article summarizes what controlled studies and meta-analyses actually show about mesenchymal stem cell (MSC) augmentation of rotator cuff repair and tendon injuries, who tends to be studied as a candidate, and — critically — the fact that these procedures remain outside FDA approval in the United States.

How It's Thought to Work

Tendons and the tendon-to-bone junction heal slowly and often imperfectly, which is why a meaningful share of surgically repaired rotator cuffs re-tear even after a technically successful operation. The theory behind stem cell augmentation is that mesenchymal stem cells — most often harvested from the patient's own bone marrow or fat tissue — can be delivered directly to the repair site during or after surgery, where they may help recruit healing factors, modulate local inflammation, and support the formation of more organized, tendon-like tissue at the bone interface rather than the weaker scar tissue that typically forms. In practice this usually means bone-marrow aspirate concentrate injected into the repair site during arthroscopic surgery, or, for tendinopathy without a full tear, an ultrasound-guided injection of cultured adipose-derived cells directly into the damaged tendon.

What the Evidence Shows

The strongest and longest-followed dataset comes from orthopedic surgeon Philippe Hernigou and colleagues, who followed 90 patients undergoing arthroscopic rotator cuff repair — 45 augmented with bone-marrow-derived MSCs and 45 matched controls — for a full ten years. The results were striking: at final follow-up, 87% of the MSC-augmented repairs remained intact versus just 44% of controls, and healing at six months was seen in 100% of the stem cell group compared with 67% of controls (published in International Orthopaedics). A more recent 2025 meta-analysis pooling five comparative studies and 415 patients found the same pattern held up across a broader body of research: retear rates were 17.7% in the MSC-augmented group versus 35% in isolated repair (a statistically significant difference), while pain scores, shoulder flexion, external rotation, and UCLA functional scores were essentially equivalent between groups. In other words, the cells appear to help the repair hold together structurally, even though patients in both groups tend to feel and function similarly well afterward. For tendinopathy rather than full tears, a small pilot study of 19 patients with chronic tennis elbow who had failed conservative treatment showed pain scores dropping from 6.28 to 0.74 (on a 0–10 scale) and QuickDASH disability scores improving from roughly 51 to under 6 over twelve months, with all 18 patients who completed follow-up returning to competitive play (published in the Journal of Experimental Orthopaedics). These are genuinely encouraging numbers, though it's worth noting the elbow study was small, uncontrolled, and industry-adjacent in design — the kind of result that needs replication in a larger randomized trial before it can be called definitive.

Who Might Be a Candidate

• Patients undergoing arthroscopic rotator cuff repair who are considered at higher risk of re-tear (larger tears, older age, poor tissue quality)
• People with chronic tendinopathy (such as lateral elbow/tennis elbow or patellar tendinopathy) who have failed months of conservative treatment like physical therapy, rest, and PRP or corticosteroid injections
• Patients being treated within a formal clinical trial or research protocol, where cell dose, harvesting method, and outcomes are tracked
• Those who understand this is not a substitute for surgery in a full-thickness tear requiring repair, but an adjunct used alongside it
• Patients who have discussed regulatory status and realistic expectations with a qualified orthopedic specialist rather than a direct-to-consumer stem cell clinic

Bottom Line

The evidence for MSC augmentation of rotator cuff repair is more encouraging than in most orthopedic stem cell applications — long-term data from Hernigou's cohort and a 2025 meta-analysis of 415 patients both point to meaningfully lower re-tear rates without any added functional benefit or apparent harm. Adipose-derived cell injections for tendinopathy also show promising early results, though the evidence base there is thinner and needs larger, controlled trials. None of this changes the regulatory picture: the FDA has not approved stem cell or regenerative medicine products for any orthopedic condition, including tendonitis and shoulder pain, and it has explicitly warned that unlicensed clinics marketing these treatments as safe and effective may be doing so illegally, with risks including infection, tumor growth, and other serious complications. Patients considering this route should look for a formal clinical trial or a specialist using bone-marrow concentrate as a surgical adjunct — not an unregulated injection sold as a standalone cure.